Elena A. Pronina

Elena A. Pronina

Auto-generated profile, based on publicly available information

Elena A. Pronina

Shared Core Facilities Molecular and Cell Technologies, V.F. Voino-Yasenetsky Krasnoyarsk State Medical University, 660022 Krasnoyarsk, Russia

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 January 2022 in Healthcare
Verified
Journal Article
Open access
PDF file
Mustafa Al-ZamilMustafa Al-Zamil
Mustafa Al-Zamil
IMInessa Minenko
Inessa Minenko
NKNatalia G. Kulikova
Natalia G. Kulikova
MAMichael Alade
Michael Alade
MPMarina Petrova
Marina Petrova
Natalia A. ShnayderNatalia A. Shnayder
Natalia A. Shnayder
Background: Transcutaneous electrical nerve stimulation (TENS) is presently one of the main methods of treatment for neuropathic pain in type II diabetes mellitus. The discussion about which TENS frequency is more effective in the treatment of neuropathic pain has been ongoing for many years. Despite this, the response of different aspects of neuropathic pain to various TENS modalities has not been sufficiently studied. Aim: To analyze changes in characteristics of neuropathic pain depending on the frequency of TENS. Materials and methods: Seventy-five Russian diabetic patients with painful distal axonal neuropathy were enrolled in the study. Patients were assigned to three groups: in the HF TENS group, 25 patients received standard drug therapy (Alpha-lipoic acid, Pentoxifylline, Vitamin B12, Gabapentin) + high-frequency TENS (HF); in the LF TENS group, 25 patients received standard drug therapy (Alpha-lipoic acid, Pentoxifylline, Vitamin B12, Gabapentin) + low-frequency TENS (LF); in the control group, 25 patients underwent just standard drug therapy (Alpha-lipoic acid, Pentoxifylline, Vitamin B12, Gabapentin). Pain intensity was calculated before and after treatment with visual analogue scale (VAS), McGill pain questionnaire (MPQ), Douleur Neuropathique 4 Questions (DN4) and Pain Drawing. Results: TENS increased the therapeutic effect of standard drug therapy, in the treatment of neuropathic pain, by 65.9% and prolonged its efficacy by 31% for up to 6 months after treatment. HF TENS had a more pronounced analgesic effect than LF TENS based on VAS (34.7%), sensory (57.6%) MPQ dimensions and DN4 (21%). Affective MPQ dimension with the use of LF TENS was lower than HF TENS by 34.7% immediately after treatment, by 47.3% after 2 months and by 34.8% after 6 months of the follow-up period. Conclusion: There are significant differences between HF and LF TENS based on pain assessment using various pain scales. This reflects the distinctive effects of different TENS modalities on different aspects of neuropathic pain.

5 August 2022 in Metabolites
Verified
Journal Article
Open access
PDF file
Aiperi Kylychbekovna KhasanovaAiperi Kylychbekovna Khasanova
Aiperi Kylychbekovna Khasanova
VDVera S. Dobrodeeva
Vera S. Dobrodeeva
Natalia A. ShnayderNatalia A. Shnayder
Natalia A. Shnayder
MPMarina Petrova
Marina Petrova
EPElena A. Pronina
Elena A. Pronina
RNRegina F. Nasyrova
Regina F. Nasyrova
Metabolic syndrome (MetS) is a clustering of at least three of the following five medical conditions: abdominal obesity, high blood pressure, high blood sugar, high serum triglycerides, and low serum high-density lipoprotein (HDL). Antipsychotic (AP)-induced MetS (AIMetS) is the most common adverse drug reaction (ADR) of psychiatric pharmacotherapy. Herein, we review the results of studies of blood (serum and plasma) and urinary biomarkers as predictors of AIMetS in patients with schizophrenia (Sch). We reviewed 1440 studies examining 38 blood and 19 urinary metabolic biomarkers, including urinary indicators involved in the development of AIMetS. Among the results, only positive associations were revealed. However, at present, it should be recognized that there is no consensus on the role of any particular urinary biomarker of AIMetS. Evaluation of urinary biomarkers of the development of MetS and AIMetS, as one of the most common concomitant pathological conditions in the treatment of patients with psychiatric disorders, may provide a key to the development of strategies for personalized prevention and treatment of the condition, which is considered a complication of AP therapy for Sch in clinical practice.

5 April 2012 in Journal of the Neurological Sciences
Verified
Journal Article
Closed access
MPMarina Petrova
Marina Petrova
SPSemen Prokopenko
Semen Prokopenko
EPElena Pronina
Elena Pronina
EMElena Mozhejko
Elena Mozhejko

1 January 2024 in Doctor.Ru
Verified
Journal Article
Open access
PUProf. V.F. Voino-Yasenetsky Krasnoyarsk State Medical University
Prof. V.F. Voino-Yasenetsky Krasnoyarsk State Medical University
EHE.I. Harkov
E.I. Harkov
RKRussian Federation Krasnoyarsk Interregional Clinical Hospital Of Urgent Medical Care Named After N.S. Karpovich; Krasnoyarsk
Russian Federation Krasnoyarsk Interregional Clinical Hospital Of Urgent Medical Care Named After N.S. Karpovich; Krasnoyarsk
NTN.YU. Tsibulskaya
N.YU. Tsibulskaya
EPE.A. Pronina
E.A. Pronina
ERE.I. Riabkov
E.I. Riabkov
Aim. To demonstrate the possibility of the influence of metabolic disorders on the formation of type 2 myocardial infarction in a young woman using a clinical example. Key points. Acute myocardial infarction in young women may not be diagnosed due to low alertness of doctors and patients themselves, since this pathology is rare at this age. However, over the past decade, the prevalence of myocardial infarction in young women has increased. The presented clinical case demonstrates the development of atherosclerotic coronary lesion with critical stenosis of the coronary artery in a 31-year-old woman, which required its endoprosthetics. The lesion manifested itself with a typical clinical picture of newly developed angina, but the patient herself assessed these symptoms incorrectly, which led to late hospitalization and the development of myocardial infarction. Acute myocardial infarction was briefly preceded by an unfavorable metabolic background: impaired carbohydrate metabolism, abdominal obesity, hypothyroidism. Conclusion. Despite the low incidence of ischemic heart disease in young women, it is necessary to be alert in the presence of myocardial ischemia symptoms in this group of patients, especially in the presence of metabolic disorders. The most important are carbohydrate metabolism disorders, abdominal obesity, and hypothyroidism. Abdominal obesity, accompanied by metabolic disorders, may be one of the possible potentially controllable risk factors for myocardial infarction in young women. Keywords: myocardial infarction, young women, abdominal obesity.

1 January 2024 in Doctor.Ru
Verified
Journal Article
Open access
PUProf. V.F. Voino-Yasenetsky Krasnoyarsk State Medical University
Prof. V.F. Voino-Yasenetsky Krasnoyarsk State Medical University
EPE.A. Pronina
E.A. Pronina
RKRussian Federation Krasnoyarsk Interregional Clinical Hospital Of Urgent Medical Care Named After N.S. Karpovich; Krasnoyarsk
Russian Federation Krasnoyarsk Interregional Clinical Hospital Of Urgent Medical Care Named After N.S. Karpovich; Krasnoyarsk
NSNatalya Shimokhina
Natalya Shimokhina
MPMarina Petrova
Marina Petrova
Aim. To study the incidence and risk factors associated with asthenia in patients with type 2 diabetes mellitus (DM2) in real-time clinical practice. Design. Cross-sectional clinical study. Materials and methods. 2373 patients were examined for symptoms of asthenia in outpatient settings; these patients were followed up by primary care physician therapeutics for chronic non-communicable diseases (CNCD). A group of DM2 patients (n = 527) was separated from this cohort. All patients were interviewed; their medical information was collected; their systems and organs were examined; and medical records were reviewed. A diagnosis of CNCD was confirmed on the basis of results and current clinical recommendations. Asthenia and its intensity were identified using the Multidimensional Fatigue Inventory 20 (MFI-20) and Fatigue Severity Scale (FSS). Results. The incidence of asthenia in DM2 patients was 38.52 % (n = 203) on MFI-20 and 26.76 % (n = 141) on FSS. The most common disorders on MFI-20 were: General Asthenia (20.11 %; n = 106), Physical Asthenia (16.13 %; n = 85) and Hypoactivity (13.09 %; n = 69). Presence of symptoms of asthenia in DM2 patients was associated with elderly age (60.0 (48.0; 68.0) vs. 53.0 (45.0; 64.0) years old in patients without asthenia; р < 0.0001) and multimorbidity: a history of acute myocardial infarction was observed in 7.88 % of patients with asthenia vs. 0.62 % of patients without asthenia (p < 0.00001), acute cerebrovascular accident — 5.91 % vs. 0.31 % (p < 0.0001), malignancies — 15.76 % vs. 1.54 % (p < 0.000001). DM2 patients with symptoms of asthenia were more often smokers vs. patients without asthenia (30.05 % and 20.68 %, respectively; p < 0.05), monitored their blood pressure regularly (65.02 % and 49.07 %; p < 0.001), took antihypertensives (45.32 % and 25.00 %; p < 0.00001) and statins regularly (34.48 % and 15.74 %; p < 0.00001). Conclusion. Asthenia is common in DM2 patients seeking outpatient medical assistance. Age-associated multimorbidity requiring longterm sophisticated treatment strategies and constant control of a number of parameters is probably one of the causes of asthenia in this patient category. Keywords: asthenia, type 2 diabetes mellitus, risk factors.